Cayuga Closes $8M Seed Funding & Doses First Patient in Phase 1 Clinical Trial

We’re excited to share two major milestones from our SOSV portfolio company Cayuga, which is developing a novel therapeutic approach to address life-threatening hemorrhage.Hemorrhage causes nearly 2 million deaths each year worldwide, and remains a l...